300119 Stock Overview
Engages in the research and development, production, and sale of veterinary raw materials, drug preparation, functional additives, and veterinary biological products. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 2/6 |
Financial Health | 5/6 |
Dividends | 6/6 |
Tianjin Ringpu Bio-Technology Co.,Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥18.30 |
52 Week High | CN¥20.68 |
52 Week Low | CN¥11.25 |
Beta | 0.71 |
11 Month Change | 20.79% |
3 Month Change | 51.87% |
1 Year Change | 5.23% |
33 Year Change | -18.12% |
5 Year Change | 29.70% |
Change since IPO | 20.14% |
Recent News & Updates
Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)
Nov 05These 4 Measures Indicate That Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Is Using Debt Reasonably Well
Oct 30Recent updates
Solid Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)
Nov 05These 4 Measures Indicate That Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Is Using Debt Reasonably Well
Oct 30The Market Lifts Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares 36% But It Can Do More
Oct 08Tianjin Ringpu Bio-Technology Co.,Ltd. Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected
Aug 26Improved Earnings Required Before Tianjin Ringpu Bio-Technology Co.,Ltd. (SZSE:300119) Shares Find Their Feet
Aug 23Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119) Seems To Use Debt Quite Sensibly
Jun 26Impressive Earnings May Not Tell The Whole Story For Tianjin Ringpu Bio-TechnologyLtd (SZSE:300119)
Apr 05Tianjin Ringpu Bio-Technology Co.,Ltd.'s (SZSE:300119) Subdued P/E Might Signal An Opportunity
Mar 28Shareholder Returns
300119 | CN Pharmaceuticals | CN Market | |
---|---|---|---|
7D | -4.2% | -1.5% | -2.1% |
1Y | 5.2% | -9.4% | 2.8% |
Return vs Industry: 300119 exceeded the CN Pharmaceuticals industry which returned -9.4% over the past year.
Return vs Market: 300119 exceeded the CN Market which returned 2.8% over the past year.
Price Volatility
300119 volatility | |
---|---|
300119 Average Weekly Movement | 8.9% |
Pharmaceuticals Industry Average Movement | 7.4% |
Market Average Movement | 8.4% |
10% most volatile stocks in CN Market | 12.7% |
10% least volatile stocks in CN Market | 5.7% |
Stable Share Price: 300119 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 300119's weekly volatility (9%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 2,496 | Lei Xu | www.ringpu.com |
Tianjin Ringpu Bio-Technology Co.,Ltd. engages in the research and development, production, and sale of veterinary raw materials, drug preparation, functional additives, and veterinary biological products. The company provides vaccines and drugs for poultry, waterfowl, livestock, and other animals; pet products comprising insect repellent series, ear products, nutritional supplements, anesthesia for surgery, anti-infective, antiviral, benazepril hydrochloride chewable tablets, meloxicam tablets, benzyl trimethylammonium chloride solution, etc.; and waterfowl products, including duck tempusu live/inactivated vaccine, gosling plague refined egg yolk antibody, duck infectious serositis inactivated vaccine, duck viral hepatitis refined egg yolk antibody, duck plague live vaccine, swine fever vaccine, etc. It offers ruminant products comprising cefquinome sulfate breast injection, ceftiofur hydrochloride injection, foot bath, nitrofenac injection, etc.; livestock products comprising ceftiofur injection, florfenicol powder, compound amoxicillin powder, tyvalin tartrate premix, carbasalate calcium soluble powder, florfenicol injection, etc.; and APIs comprising tilmicosin, tilmicosin phosphate, totrazuli, florfenicol, warnemulin hydrochloride, etc. In addition, the company provides potassium persulfate complex powder, concentrated glutaraldehyde solution, decyl ammonium bromide solution, and glutaraldehyde decyl ammonium bromide solution.
Tianjin Ringpu Bio-Technology Co.,Ltd. Fundamentals Summary
300119 fundamental statistics | |
---|---|
Market cap | CN¥8.48b |
Earnings (TTM) | CN¥423.98m |
Revenue (TTM) | CN¥2.41b |
19.9x
P/E Ratio3.5x
P/S RatioIs 300119 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300119 income statement (TTM) | |
---|---|
Revenue | CN¥2.41b |
Cost of Revenue | CN¥1.24b |
Gross Profit | CN¥1.17b |
Other Expenses | CN¥747.75m |
Earnings | CN¥423.98m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 0.92 |
Gross Margin | 48.65% |
Net Profit Margin | 17.60% |
Debt/Equity Ratio | 25.7% |
How did 300119 perform over the long term?
See historical performance and comparison